IAG, Image Analysis Group is a valuede partner to life sciences companies. Our goal is to accelerate novel drug developments, by using the right analytical tools and a modern trial infrastructure.
At IAG, we are committed to helping our biotech and pharma partners to efficiently develop novel life-changing medicines, accelerating their R&D pipelines through advanced analytics, IAG’s technology solutions and imaging contract research services.
IAG’s foundation is in software development, use of Artificial Intelligence and data sciences applied to medical imaging.
Today, IAG helps clients in optimizing clinical trial designs with imaging-based methodologies that can accelerate go / no-go efficacy decisions for emerging therapeutics and enrich patient selection in musculoskeletal, oncology, immunology, rheumatology, CNS and rare disease trials.
IAG’s proprietary technology platform DYNAMIKA, developed to maximize efficiencies of handling imaging data in multi-centre clinical trials is used by pharmaceutical companies, CROs, biotechnology companies, and academics worldwide.
Smart use of novel approaches for central image review and our modern trial infrastructure ensure the speed and cost-effectiveness of phase I-VI trial execution, while delivering insights about novel mechanisms of action and patients’ response, in real-time.
IAG’s teams together with its world-class Scientific Advisory Board closely to work with our life science partners in addressing their goals of smart trial design, efficient execution and transparent processes.
We are here to create successful partnerships and to see more patients cured with the drugs, that we can help you to develop.